Latest News

Washington, DC– Congressman Brett Guthrie (KY-02), vice chair of the House Energy and Commerce Committee’s Health Subcommittee, today released a statement following the U.S. Food and Drug Administration (FDA) announcement regarding plans to finalize guidance clarifying the scope of permissible communications between biopharmaceutical companies, health plans and similar entities.

“Last year, I introduced the Pharmaceutical Information Exchange Act (H.R. 2026) because I recognized the need for better communication and data sharingbetween biopharmaceutical companies and health insurers. I look forward to reviewing the final guidance from FDA and hope that it provides additional clarity needed for these important conversations to occur in a timely and meaningful manner. We must acknowledge the importance of health insurance companies fully understanding the value and costs associated with covering innovative new products as soon as possible to get potentially lifesaving treatments into the market. While this guidance is a welcome step in the right direction, H.R. 2026 is still needed to provide stakeholders with statutory certainty, and I look forward to continuing to work with my colleagues on both sides of the aisle to advance this important legislation.”

###